Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

NCT05764395 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Refractory Melanoma
Unresectable Melanoma

Interventions

DRUG: Rigosertib
BIOLOGICAL: Pembrolizumab
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Biospecimen Collection
PROCEDURE: Biopsy

Sponsor

Vanderbilt-Ingram Cancer Center